E7070

DRUG7 trials

Sponsors

Eisai Inc., Eisai Co., Ltd., Eisai Limited, M.D. Anderson Cancer Center

Conditions

Adenocarcinoma, Renal CellBreast NeoplasmsCarcinoma, Renal CellColorectal CancerColorectal Cancer (CRC)Gastric CancerKidney NeoplasmsLeukemia

Phase 1

A Study of E7070 in Patients With Gastric Cancer

TerminatedNCT00165594

Eisai Co., Ltd.Gastric Cancer

Start: 2005-02-28End: 2006-08-31Target: 50Updated: 2014-01-23

Phase 2

A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma

CompletedNCT00059735

Eisai Inc.Adenocarcinoma, Renal Cell, Carcinoma, Renal Cell, Kidney Neoplasms

Start: 2002-05-31End: 2003-12-31Updated: 2008-03-05

Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients

CompletedNCT00080197

Eisai Inc.Breast Neoplasms, Metastases

Start: 2004-02-29End: 2005-05-31Target: 250Updated: 2006-10-11

Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer

CompletedNCT00165854

Eisai LimitedColorectal Cancer (CRC)

Start: 2003-03-31Target: 46Updated: 2014-06-27

An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine

TerminatedNCT00165880

Eisai LimitedMetastatic Breast Cancer

Start: 2004-12-31End: 2007-09-30Updated: 2014-07-01

An Open Label Phase II Study of Indisulam in Combination With Irinotecan in Patients With Metastatic Colorectal Cancer Who Have Been Previously Treated With 5-Fluorouracil/Leucovorin and Oxaliplatin

CompletedNCT00165867

Eisai LimitedColorectal Cancer

Start: 2005-04-30Target: 40Updated: 2006-10-09

E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes

CompletedNCT01692197

M.D. Anderson Cancer CenterLeukemia

Start: 2013-02-01End: 2017-06-07Updated: 2018-07-03